Manufacturing

Yourway intends to construct a new manufacturing facility in the Dublin Airport Logistics Park.

REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.

Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.

The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.

Eli Lilly and Company plans to build two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

Pfizer will invest $120 million to produce COVID-19 oral treatment in the US.

One can use modeling methods to generate data and shorten development timelines in preclinical studies.

Advances in genomics tools can lead to quicker biotherapeutic development.

Demand spurs innovations in syringes and syringe fill/finish operations.

Precompetitive consortiums seek solutions to industry-wide challenges.

The KTEvolution from Tower Cold Chain is a lightweight, reusable container designed for the transport of pharmaceutical products.

Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.

AI could provide solutions to critical manufacturing inefficiencies.

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.

The agency is asking drug manufacturers to ensure a strong supply chain by developing risk management plans.

Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.

The new company has been appointed as a channel partner for Ireland by TSI Inc., a particle counter manufacturer.

An increasingly complex development pipeline and industry considerations, such as sustainability, are leading to a greater need for more efficient separation and purification in downstream processing.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.